

# Investigating the Role of Metoclopramide and Hyoscine-N-Butyl Bromide in Colon Motility

Sleman Y. Omar<sup>1</sup>, Dyari M. Mamand<sup>2</sup>, Rebaz A. Omer<sup>3</sup>, Rzgar F. Rashid<sup>4</sup> and Musher I. Salih<sup>3</sup>

<sup>1</sup>Department of Biology, College of Science, University of Raparin,  
Sulaymaniyah, Kurdistan Region – F.R. Iraq

<sup>2</sup>Department of Physics, College of Science, University of Raparin,  
Sulaymaniyah, Kurdistan Region – F.R. Iraq

<sup>3</sup>Department of Chemistry, Faculty of Science and Health, Koya University,  
Danielle Mitterrand Boulevard, Koya KOY45, Kurdistan Region – F.R. Iraq

<sup>4</sup>Department of Medical Laboratory Science, College of Science, Knowledge University,  
Erbil, 44001, Kurdistan Region – F.R. Iraq

**Abstract**—Metoclopramide is a treatment for gastroenteritis accompanied by vomiting. Hyoscine-n-butyl bromide as an anticholinergic agent causes inhibition of the acetylcholine (Ach) by acting on muscarinic receptors. The study aims to ascertain how metoclopramide affects Ach-induced cortical motility and also investigates the effects of metoclopramide alone and in combination with hyoscine-n-butyl bromide drug effects on colon motility. In this study, 1 cm of colon tissue width was cut, 2 cm long strips were made, and both sides of the tissue were secured with surgical silk at both ends of isolated bath tissues of isolated organs with (1 g) tension to the suspended instrument that recorded isometric contractions. Tissue fixation is followed by drug addition: Ach, metoclopramide, and hyoscine-N-butyl bromide. The tissue was treated with metoclopramide and hyoscine-n-butyl bromide and excess Caine for 10 min. The results show changes in colon frequency, peak-to-peak, and amplitude levels for metoclopramide, hyoscine-N-butyl, and metoclopramide and hyoscine. A paired T-test statistically analyzes the results. Metoclopramide by itself, as well as in combination with hyoscine-n-butyl bromide, increases colon motility and induces Ach release. In addition, an analysis of the physicochemical characteristics of hyoscine-n-butyl bromide and metoclopramide molecules is conducted. The study includes theoretical calculations of electronic parameters for both protonated and unprotonated forms of these molecules in both gaseous and aqueous environments. These results show the potential use of metoclopramide as a therapeutic option for gastroenteritis with vomiting, warranting additional study, and clinical evaluation. The research also reveals hyoscine-n-butyl bromide and metoclopramide's molecular features by their physicochemical properties.

**Index Terms**—Acetylcholine, Colon, DFT, Hyoscine-N-butyl bromide, Metoclopramide.

## I. INTRODUCTION

Smooth muscle is a type of muscle tissue whose movements are spontaneous and involuntary. Cells have a single nucleus located in the middle of the cell. Smooth muscle is composed of thin and thick fibers so uniform appear cells (Phillips, 1984). Approximately 10% of the human body's muscle composition consists of smooth muscle, found in organs such as the digestive tract, intestines, and bladder. Although the symptoms of smooth muscle contraction resemble those of skeletal muscle contraction, the structural and internal characteristics of smooth muscle fibers differ significantly. Within the stomach and intestines, muscle fibers play a crucial role in aiding the process of digestion and the absorption of nutrients. In the urinary system, it is also responsible for electrolyte balance and regulating the elimination of waste and harmful substances from the body (Williams and Rubin, 2018, Giuseppe, Paul and Hans-Ulrich, 2015). Smooth muscle is present in all arteries and veins and has an important function in controlling blood pressure and tissue respiration. The human colon performs several majestic and important functions, such as fixation of nutrients, utilization of water and electrolytes, storage of stool contents, and timely excretion (Phillips, 1984). The cortical muscle needs to be activated in a well-coordinated and controlled manner for these processes to occur. Moreover, some medications such as metoclopramide can help and support gastric emptying by stimulating smooth muscle activity (Williams and Rubin, 2018, Giuseppe, Paul and Hans-Ulrich, 2015). The ascending colon expands superiorly until coming to a halt at the right colic flexure (hepatic flexure), which is located close to the liver's inferior right edge (Macfarlane, Gibson and Cummings, 1992). The descending colon rises from the

ARO-The Scientific Journal of Koya University  
Vol. XI, No. 2 (2023), Article ID: ARO.11375. 7 pages  
DOI: 10.14500/aro.11375

Received: 03 September 2023; Accepted: 18 October 2023  
Regular research paper: Published: 10 November 2023

Corresponding author's e-mail: musher.ismael@koyauniversity.org  
Copyright © 2023 Sleman Y. Omar, Dyari M. Mamand, Rebaz A. Omer, Rzgar F. Rashid and Musher I. Salih. This is an open access article distributed under the Creative Commons Attribution License.



left colic flexure to the anterior aperture of the true pelvis, where it creates the sigmoid colon, whereas the transverse colon spreads from the right colic flexure to the left colic flexure. An S-shaped tube that extends into the pelvis and terminates at the rectum is formed by the descending colon (Cody, 2001).

Metoclopramide (Fig. 1) is an important antiemetic drug and is also used as a treatment to stimulate stomach movements. Metoclopramide is indicated for the treatment of individuals with gastroesophageal reflux disease and gastrectomy has been associated with metoclopramide, as described by (Maltepe and Koren, 2013). Metoclopramide is characterized as a dopamine (D2) receptor antagonist with a brief half-life, and it possesses dual properties as both a 5HT3 and 5HT4 receptor antagonist. Its effects encompass antiemetic, antidiarrheal, and gastromotor properties (Smith and Laufer, 2014). Meanwhile, the ability of metoclopramide to affect colon motility remains controversial. Metoclopramide enhanced withdrawal frequency in round sections of the human and animal cortex through smooth muscle contraction *in vitro* (Schulze-Delrieu, 1979).

In clinical practice, stomach pains are treated with hyoscine-n-butyl bromide (buscopan) (Fig. 2), which is an antispasmodic agent of the muscle. It is particularly involved in gastrointestinal inflammation, for example, those with leukemia, especially bowel obstruction and irritable bowel syndrome. They are also used effectively as smooth muscle relaxants and anticholinergic and calcium channel blockers and are very effective in treating conditions associated with stomach pain (Samuels, 2009). Known as hyoscine-n-butyl bromide (scopolamine butyl bromide, Buscopan) that is used to treat smooth muscle relaxation and anticholinergic properties (Hasan, et al., 2013). Example of muscle M2 and M3 receptors has a very good effect on them so hyoscine-n-butyl bromide in smooth muscle causes gastrointestinal tract. Hyoscine-N-butylbromide according to its sustained actions




Fig. 1. Chemical formation of metoclopramide is strictly associated with procainamide.




Fig. 2. Chemical formation of hyoscine-N-butyl bromide.

being anti-smooth muscle contraction can inhibit nicotinic receptor in SH-SY5Y cells and human enteric neurons (DeLoid, et al., 2017). In addition, a unique kinematic study of muscle contraction and relaxation was conducted to examine the effects of hyoscine-n-butyl bromide on the digestive system, especially the abdominal colon (Dicken, et al., 2011). To facilitate the long-term preservation of ingested material and promote microbial aging, the complex functioning of the digestive system requires the integration of its kinetics. Therefore, any increase in bowel motility in these areas makes a person more vulnerable (Hasan, et al., 2013).

## II. MATERIALS AND METHODS

### A. Study Design

In the study, for colon tissue recordings, eight animals were utilized from the Firat University Experimental Research Center located in ELAZIĞ, with each animal's tissue strips serving as respective controls. Waited for 10–12 weeks until the mice had reached an average weight ranging between 180 and 200 g. Following the decapitation of the mice, the abdominal area promptly excised and the colon tissues were removed. These colon tissues were subsequently placed in a Petri dish containing Krebs solution. In this study, smooth muscle was focused on the animals that were euthanized without the use of anesthesia to prevent any potential impact on the smooth muscle.

### B. Experimental Setup

The study utilizes a two-chamber organ bath system, enabling the concurrent utilization of two separate smooth muscle strips. This setup comprises several essential components, including the organ bath itself, an amplifier, a recorder, a circulating pump equipped with a thermostat, and a source of oxygen and carbon dioxide. Designed to replicate physiological conditions within a laboratory environment, Krebs's solution incorporates specific elements that support the retention of contractility properties in smooth muscle cells when studied *in vitro*. The Krebs solution is prepared in mmol/L and the pH is adjusted to 7.4 of NaCl: 118, KCl: 4.7 mmol/L, MgSO<sub>4</sub>: 1.2 mmol/L, Glucose: 11.5 mmol/L, CaCl<sub>2</sub>: 2.4 mmol/L, KH<sub>2</sub>PO<sub>4</sub>: 1.18 mmol/L, EDTA: 0.016 mmol/L, and NaHCO<sub>3</sub>: 2.0 mmol/L.

### C. Preparation and Application Protocol of Colon Tissues

After euthanizing male animals, their abdominal areas were carefully opened, and a 1 cm wide incision was made in the colon cecum. A 2 cm long strip of tissue was then meticulously prepared and affixed to both ends of silk sutures, which were embedded at either end of the isolated organ bath. A tension of 1.0 g was applied to the device, which was suspended and used to record isometric contractions. Following this, we allowed 1.5 hours for the colon strips to acclimate. During this time, tissues in the isolated organ baths were subjected to a 15-min treatment with Krebs solution. Once sustained spontaneous contractions became observable, we induced contractions by adding acetylcholine (Ach) at

a dose of 10–4M. Subsequently, we conducted experiments in three distinct protocols after the adjustment period. In the first protocol, we added 35 μM of metoclopramide to the Ach-stimulated colon strips, followed by 15 μM of hyoscine-n-butyl bromide to the same strips after 1 h. Finally, 1 h later, both hyoscine-n-butyl bromide and metoclopramide were simultaneously administered to the Ach-stimulated colon strips. We carefully recorded and analyzed the effects of metoclopramide alone and hyoscine-n-butyl bromide on colonic contractility, with the tissue contraction values before drug administration serving as their respective controls.

*D. Organ Bath Containers*

Divided into two interconnected parts. In addition, the heater contains hot water within the space between these two layers. Inside the inner compartment, you will find Krebs solution along with the smooth muscle strips utilized in the research. The cortex strip is suspended between two hooks, one within the chamber and the other outside, using a silk thread.

*E. Thermocirculator*

It is placed in heat-circulated purified water at 36.7°C. The heated water goes to the area where the Krebs solution is stored and goes to the warehouses in various ways. Because the Krebs solution is stored in two regions, the spaces and reservoirs are intertwined and there are gaps between the layers. The thermostat sensitivity ranges from 36.7 ± 0.1°C. The circulating heated water circulates in this space to keep the environment at body temperature.

*F. Oxygen carbon dioxide source*

A gas mixture required for *in vitro* smooth muscle contraction is ideally made of 95% O<sub>2</sub> and 5% CO<sub>2</sub>. In the isolated organic bath and recording system, the O<sub>2</sub> and CO<sub>2</sub> contents prepared in this mixture were continuously circulated to the chamber.

*G. Statistical Analysis*

Statistical analysis was performed using SPSS software, version 24. For comparison of uptake values (independent test). The significance level used was p = 0.05).

III. RESULTS AND DISCUSSION

*A. Effects of Metoclopramide and Hyoscine-n-butyl Bromide on Frequency of Smooth Muscle Contraction and Relaxation in Colon*

The results provided evidence that all doses of metoclopramide, hyoscine-N-butyl bromide, and a combination of the two were statistically significant (p < 0.05). Specifically, the mean frequency (mean ± SE) of isolated Ach-induced colon strips was 151.5021.38 (n = 8) for 35M metoclopramide, 127.0510.09 (n = 8) for 15 M hyoscine-N-butyl bromide, and 242.3255.00 (n = 8) for 50 M of the mixed concentration. The highest frequency of isolated Ach-induced colon strips was observed in the

combination of metoclopramide and hyoscine-N-butyl bromide, as indicated in Table I.

*B. Effects of metoclopramide and hyoscine-n-butyl bromide on Pile peak (peak-to-peak) on smooth muscle contraction and relaxation in the colon*

Sections of rat colon tissues were tested by treating and administering drugs with 35 μM metoclopramide, 15 μM hyoscine-n-butyl bromide in each drug separately, then by mixing both drugs at 50 μM. The mean and standard deviation error for peak-to-peak of isolated Ach-induced cortical strips from control and treated mice was 62.364.35 (n = 8), 67,225.84 (n = 8), and 73.576.23 (n = 8), respectively. All drugs caused a significant decrease in peak-to-peak static compared with control (35 μM metoclopramide: p < 0.001; 15 μM hyoscine-N-butyl bromide: p < 0.001; 50 μM: p < 0.05). metoclopramide 35 μM showed the most significant reduction compared with other drugs, as shown in Table II.

*C. Effects of Metoclopramide and Hyoscine-n-butyl Bromide on Smooth Muscle Contraction and Relaxation in the Colon*

Results from this analysis are mean ± SE of 48.27 ± 11.42 (n = 8), 46.06 ± 8.75 (n = 8), and 29.28 ± 4.65 (n = 8) for the amplitude of Ach-induced isolated contractile strips, contractile muscle shoulder in rats with 35 μM metoclopramide and 15 μM hyoscine-1. N-butyl bromide we also control 50 μM hyoscine-n-butyl bromide and metoclopramide by combining the two drugs. All of these doses were statistically significant compared with the control, as 35 μM metoclopramide showed the least reduction in muscle contractility (p < 0.05). Relative to the combination of both drugs with 50 μM metoclopramide and hyoscine-n-butyl bromide had the greatest reduction (p < 0.001), as shown in Table III. One dose that captures

TABLE I  
SHOWS MEAN±SE AND P VALUE OF FREQUENCY, BEFORE AND AFTER TREATMENT IN COLON CONTRACTION STRIPS

Dose	Frequency	N	Mean±SE	p
(35μm) Metoclopramide	Before treat.	8	115.352±16.532	0.047
	After treat.		151.507±21.387	
(15 μm) hyoscine-n-butyl bromide	Before treat.	8	98.341±9.220	0.032
	After treat.		127.056±10.093	
(35 μm) metoclopramide+(15 μm) hyosin-n-butyl bromide	Before treat.	8	174.827±38.349	0.03
	After treat.		242.325±55.004	

TABLE II  
THE MEAN±SE AND P VALUE OF PEAK-PEAK, BEFORE AND AFTER TREATMENT IN DUODENUM STRIPS

Dose	Peak-peak	n	Mean±S.E	p
(35 μm) Metoclopramide	Before treat.	8	70.922±3.651	0.0001
	After treat.		62.360±4.359	
(15 μm) hyoscine-n-butyl bromide	Before treat.	8	74.591±6.508	0.001
	After treat.		67.222±5.843	
(35 μm) metoclopramide+(15 μm) hyoscine-N-butyl bromide	Before treat.	8	129.289±48.459	0.004
	After treat.		73.578±6.323	

TABLE III  
MEAN±SE AND P VALUE OF THE AREA, BEFORE AND AFTER TREATMENT  
CONTRACTION 109 COLON STRIPS

Dose	Area	N	Mean±SE	P
(35 µm) Metoclopramide	Before treat.	8	52.246±11.600	0.003
	After treat		48.275±11.432	
(15 µm) hyoscine-n-butyl bromide	Before treat.	8	52.155±8.876	0.001
	After treat.		46.063±8.751	
(35 µm) metoclopramide+ (15 µm) hyoscine -n-butyl bromide	Before treat.	8	35.132±4.647	0.001
	After treat.		29.288±4.659	

the awareness of experts in this sector is metoclopramide. Metoclopramide and its receptor are expressed in multiple organs, mainly the lung, adipose tissue, and female breast (Falcão-Pires and Leite-Moreira, 2005). The results of this study showed that metoclopramide alone and in combination with hyoscine-n-butyl bromide significantly affects slowing of the muscle in vitro in male rats. According to earlier research on the colon, contract happens when intracellular  $Ca^{+2}$  rises as a result of  $Ca^{+2}$  being released from SR and entering the cell through voltage-sensitive  $Ca^{+2}$  channels outside the cell. PLC pathways are used by several hormones that act on receptors, including OT and PGF2 (Catterall, 1988). Two-second messengers are activated by PLC activation. PKC is activated by DAG, which also releases  $Ca^{+2}$  from IP3 SR. Myosin-actin contact causes contraction when the MLCK enzyme is activated by the  $Ca^{+2}$  calmodulin compound, which also causes the phosphorylated of MLC (Sumi, et al., 1991). Actin and myosin levels reduced together with the colon's contraction upon the addition of metoclopramide alone, along with hyoscine-n-butyl bromide in the container (Sumi, et al., 1991). It is well recognized that a variety of regional and global factors influence how the colon constricts when doses are administered. Recent investigations have uncovered the varied ways in which numerous novel hormones and cytokines affect the motility of the colon (Falcão-Pires, et al., 2005). Similar to skeletal muscle, the colon cells are heavily dependent on calcium ions to control their ability to contract. However, because smooth muscle SR does not mature properly, extracellular fluid is mostly responsible for the calcium needed for contraction. Exactly before phasic contractions in the GI,  $Ca^{+2}$  entrance into the cell from the external environment raises intracellular calcium levels (Giannone, et al., 2010). It has been claimed that the availability of exogenous calcium completely determines the amount of stimulation parameters in the colon. It has been demonstrated that if there is no  $Ca^{+2}$  in the environment where duodenal segments are situated, spontaneously contracting ends abruptly and spontaneously activation diminishes. It has been noted that adding  $Ca^{+2}$  to the medium restores activation in response (Hashitani, Brading and Suzuki, 2004). Changes in underdoes levels were statistically significant in male rats. Sequentially, it was observed that the tissue was controlled by the application of 35 µM metoclopramide, 15 µM hyoscine-n-butyl bromide and by combining the drugs with 50 µM metoclopramide and hyoscine-n-butyl bromide. All dose frequencies had

a statistically significant positive effect on slowing muscle contraction. Furthermore, metoclopramide applied alone to compare with hyoscine-n-butyl bromide is preferable, because it increases the effects of metoclopramide on smooth muscle contractility, better than hyoscine-n-butyl bromide. Meanwhile, hyoscine-n-butyl bromide is more effective than the combination of both metoclopramide and hyoscine-n-butyl bromide which significantly reduces smooth muscle contraction at peak-to-peak. However, when hyoscine-n-butyl bromide was added, it showed minimal muscle contractile effects significantly compared to the dosage forms. Furthermore, the effects of metoclopramide and hyoscine-n-butyl bromide on smooth muscle contraction showed the least statistically significant reduction of cortical muscle contraction, compared with each other. Furthermore, the importance of metoclopramide only on muscle contraction in the cortex, the contraction of the region was much less effective than each other.

#### D. Electronic Structure

In drug development, physicochemical qualities are the tangible physical characteristics of molecules related to interactions with various mediums and situations. Physicochemical describes objects that include both physics and chemistry principles, implying that they rely on or are generated by the combined operations of physical and chemical qualities (Mary, et al., 2021). Throughout the study, the B3LYP density functional technique, as implemented in the Gaussian package 09, was used. Basis set 6-311G++(d,p) is used for full optimization of all geometries. With large 6-311++G(d,p) basis sets, the anionic species used in this work were produced (Fig. 3), using the continuous solvation approach, the relaxation energies of the protonated and neutral species were calculated theoretically (Mamand, et al., 2022a, Mamand and Qadr, 2021). The guide-like polarization constant variation was used to implement the polarization constant model (PCM). PCM computations were performed on the gas-phase geometries as single points (without optimization) since this has been demonstrated to produce better results than optimization. Water was given a dielectric constant of = 79.39 (Erdoğan, et al., 2017, Qadr and Mamand, 2021). A characterization of the form and size of the cavity formed by solute molecules in the solvent is required for continuum models.

Numerous novel chemical reactivity descriptors have been proposed to help understand various areas of pharmaceutical sciences such as drug design and prospective ecotoxicological physiognomies of medications. To investigate the properties of these two molecules, some important properties were calculated in this study, which is shown in Tables IV and V.

The features of frontier molecular orbitals are utilized to describe many types of reactions and to calculate the most reactive location in a conjugated system. The HOMO and LUMO energy, as well as their gap, are computed to show a complex's chemical reactivity and biological activity. The HOMO, which is thought to be the outer orbital containing electrons, has a tendency to contribute electrons as e-donors,




Fig. 3. Optimized molecule structure of hyoscine-n-butyl bromide and metoclopramide is strictly associated with procainamide based on DFT at 6-311G++(d,p) basis set.

TABLE IV  
THEORETICAL CALCULATION OF ELECTRONIC PARAMETERS FOR HYOSCINE-N-BUTYL BROMIDE AT PROTONATED AND NON-PROTONATED SPECIES IN GAS AND AQUEOUS PHASES

A	Non-protonated gas phase	Protonated gas phase	Non-protonated aqueous phase	Protonated aqueous phase
$E_{\text{HOMO}}$ (eV)	-7.20639506	-7.18054423	-5.74922459	-7.91634049
$E_{\text{LUMO}}$ (eV)	-6.570736758	-6.60910483	-5.21996286	-7.42190935
Dipole moment (Debye)	10.6328	17.7123	15.7043	23.1631
Total energy a.u	-1116.8279	-1117.0173	-1116.8121	-1116.8919
Ionization energy (eV)	7.2063	7.1805	5.7492	7.9163
Electron affinity (eV)	6.5707	6.6091	5.2199	7.4219
Band-gap energy (eV)	0.6356	0.5714	0.5292	0.4944
Hardness (eV)	0.31782	0.2857	0.2646	0.2472
Softness (eV)	3.1463	3.4999	3.7788	4.0450
Electronegativity (eV)	6.8885	6.8948	5.4845	7.6691
Chemical potential (eV)	-6.8885	-6.8948	-5.4845	-7.6691
Electrophilicity (eV)	74.6507	83.1909	56.8353	118.955
Nucleophilicity (eV) <sup>-1</sup>	0.0133	0.0120	0.0175	0.0084
Transfer electrons	-0.0794	-0.07142	-0.066	-0.0618
$\Delta E_{\text{Back-donation}}$ (eV)	0.1753	0.1840	2.8632	-1.3533
$\Delta N$	-0.0097	-0.0096	-2.1694	-0.4527
$E_{\text{MEI}}$	68.0799	76.5818	51.6153	111.5339
Nucleophugality	81.8570	90.3715	62.5845	126.8721
Electrphugality	7.2063	7.18054	5.7492	7.9163

TABLE V  
THEORETICAL CALCULATION OF ELECTRONIC PARAMETERS FOR METOCLOPRAMIDE AT PROTONATED AND NON-PROTONATED SPECIES IN GAS AND AQUEOUS PHASES

B	Non-protonated gas phase	Protonated gas phase	Non-protonated aqueous phase	Protonated aqueous phase
$E_{\text{HOMO}}$ (eV)	-7.55089139	-7.42789586	-7.60857955	-5.95902449
$E_{\text{LUMO}}$ (eV)	-6.64529599	-6.89754567	-6.92285227	-4.71328659
Dipole moment (Debye)	8.9873	9.7832	14.6734	18.5133
Total energy a.u	-1320.7281	-1320.440	-1320.4521	-1320.7801
Ionization energy (eV)	7.5508	7.4278	7.6085	5.9590
Electron affinity (eV)	6.6452	6.8975	6.9228	4.7132
Band-gap energy (eV)	0.9055	0.5303	0.6857	1.2457
Hardness (eV)	0.4527	0.2651	0.342	0.6228
Softness (eV)	2.2084	3.771093238	2.9166	1.6054
Electronegativity (eV)	7.0980	7.162720765	7.2657	5.3361
Chemical potential (eV)	-7.098	-7.1627	-7.2657	-5.3361
Electrophilicity (eV) ( $\omega$ )	55.6351	96.7371	76.9848	22.8575
Nucleophilicity (eV) <sup>-1</sup>	0.0179	0.0103	0.0129	0.0437
Transfer electrons	-0.1131	-0.0662	-0.0857	-0.1557
$\Delta E_{\text{Back-donation}}$ (eV)	-0.10831	-0.3068	-0.3874	1.33562
$\Delta N$	-0.00531	-0.0249	-0.05148	-1.1111
$E_{\text{MEI}}$	48.9898	89.8396	70.0620	18.1442
Nucleophugality	63.1860	104.1650	84.5934	28.8166
Electrphugality	7.5508	7.4278	7.6085	5.9590

and so the ionization potential is necessarily connected to the energy of the HOMO. LUMO, on the other hand, may accept electrons, and the LUMO energy is directly related to electron affinity. A high value indicates electron donation and also a high LUMO value causes the molecule to tend to accept electrons. Both molecules have the highest values for HOMO in water, which proves that the ability of these two drugs to donate electrons will be greater. A molecule with a smaller HOMO-LUMO gap is more polarizable and has low kinetic stability and strong chemical reactivity. The softness, therefore, correlates to the HOMO-LUMO gap. The softer the molecule or multicomponent crystal, the narrower the HOMO-LUMO energy gap. Figs. 4 and 5 illustrate the HOMO-LUMO energy gaps of hyoscine-n-butyl bromide has a lower bandgap energy than metoclopramide (Mamand, et al., 2022b, Omar, et al., 2023). The ( $\eta$ ) defines the conflict toward the distortion of the electron cloud of chemical systems in the presence of minor disturbances encountered throughout the chemical process (Chattaraj and Roy, 2007, Parlak, et al., 2022, Omer, Koparir and Ahmed, 2022). Electrophilicity ( $\omega$ ) is

defined as a measure of the sensitivity of chemical species to accept electrons. Low values of ( $\omega$ ) indicate the presence of a good nucleophile; whereas, higher values indicate the presence of good electrophiles. The best electrophilic molecule is in the state, where the first molecule has the highest electrophilicity in non-protonated gas and protonated water. Electrophilicity is a reactivity descriptor that may be used to define the toxicity of these compounds. It also includes a direct link between reaction rates and the ability to determine an electrophile's function or capacity. The inhibitor (A) had higher electrophilicity indices (74.65, 83.19, 56.83, and 118.95 eV) in gas and aqueous phases for protonating and non-protonated states than metoclopramide (55.63, 96.73, 76.98, and 22.85 eV), indicating that they have more biological activity. In addition, the calculations revealed that the hyoscine butyl bromide molecule has a low electronegativity (6.88, 6.89, 484, and 7.66 eV) in gas and aqueous phases for protonating and non-protonated states, which increases the electron releasing power of metoclopramide to the enzyme, and as a result, increases metoclopramide capacity to be oxidized.




Fig. 4. HOMO and LUMO of hyoscine-n-butyl bromide and metoclopramide compounds in the gas phase.




Fig. 5. HOMO and LUMO of hyoscine-n-butyl bromide and metoclopramide compounds in the aqueous phase.

## IV. CONCLUSION

The impact of metoclopramide on the contractile and relaxant responses of colon muscle induced by Ach. To achieve this, we utilized a novel experimental setup, involving 1 cm wide and 2 cm long incisions in the colon tissue attached to organ bath tissues. Ach, metoclopramide, hyoscine-n-butyl bromide, and a combination of metoclopramide and hyoscine-n-butyl bromide were sequentially applied to the colon tissue. This allowed us to observe and analyze changes in frequency, peak-to-peak, and amplitude in the muscle contractions. Using statistical analysis a paired sample T-test, providing valuable insights into the effects of metoclopramide on colon muscle responses to Ach stimulation. The results showed that metoclopramide, hyoscine-n-butyl bromide, and the combination of the two affected colonic contractility by stimulating Ach and increasing intestinal motility. Metoclopramide is thus used in the treatment of gastroenteritis. Physicochemical properties of hyoscine-n-butyl bromide and metoclopramide molecules metoclopramide bromide were found to have a higher electrophilicity index and higher electronegativity than hyoscine-n-butyl bromide, indicating that it has more biological activity and potential to deform more effectively oxidized. Therefore, it can be concluded that metoclopramide bromide is the best molecule for an anticholinergic agent.

## REFERENCES

- Catterall, W.A., 1988. Structure and function of voltage-sensitive ion channels. *Science*, 242, pp.50-61.
- Chattaraj, P.K., and Roy, D.R., 2007. Update 1 of: electrophilicity index. *Chemical Reviews*, 107, pp.PR46-PR74.
- Cody, H.S., 2001. *Sentinel Lymph Node Biopsy*. CRC Press, United States.
- Deloid, G.M., Wang, Y., Kapronezai, K., Lorente, L.R., Zhang, R., Pyrgiotakis, G., Konduru, N.V., Ericsson, M., White, J.C., and De La Torre-Roche, R., 2017. An integrated methodology for assessing the impact of food matrix and gastrointestinal effects on the biokinetics and cellular toxicity of ingested engineered nanomaterials. *Particle and Fibre Toxicology*, 14, p.40.
- Dicken, B.J., Sergi, C., Rescorla, F.J., Breckler, F., and Sigalet, D., 2011. Medical management of motility disorders in patients with intestinal failure: A focus on necrotizing enterocolitis, gastroschisis, and intestinal atresia. *Journal of Pediatric Surgery*, 46, pp.1618-1630.
- Erdoğan, Ş., Safi, Z.S., Kaya, S., Işın, D.Ö., Guo, L., and Kaya, C., 2017. A computational study on corrosion inhibition performances of novel quinoline derivatives against the corrosion of iron. *Journal of Molecular Structure*, 1134, pp.751-761.
- Falcão-Pires, I., and Leite-Moreira, A.F., 2005. Apelin: A novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. *Revista Portuguesa de Cardiologia*, 24, pp.1263-1276.
- Falcao-Pires, I., Vasconcelos, M., Magalhaes, J., Bras-Silva, C., and Leite-Moreira, A., 2005. 234 Distinct contractile effects of apelin in intact hearts and isolated papillary muscles. *European Journal of Heart Failure Supplements*, 4, pp.48-49.
- Giannone, F., Malpeli, G., Lisi, V., Grasso, S., Shukla, P., Ramarli, D., Sartoris, S., Monsurro, V., Krampera, M., and Amato, E., 2010. The puzzling uniqueness of the heterotrimeric G15 protein and its potential beyond hematopoiesis. *Journal of Molecular Endocrinology*, 44, pp.259-269.
- Giuseppe, C., Paul, J., and Hans-Ulrich, I., 2015. Use of nitrates in ischemic heart disease. *Expert Opinion on Pharmacotherapy*, 16, pp.1567-1572.
- Hasan, N., Chaiham, M., Khan, S., Khalid, H., Sher, N., Siddiqui, F.A., and Siddiqui, M.Z., 2013. Dual wavelength RP-HPLC method for simultaneous determination of two antispasmodic drugs: An application in pharmaceutical and human serum. *Journal of Analytical Methods in Chemistry*, 2013, p.297285.
- Hashitani, H., Brading, A.F., and Suzuki, H., 2004. Correlation between spontaneous electrical, calcium and mechanical activity in detrusor smooth muscle of the guinea-pig bladder. *British Journal of Pharmacology*, 141, pp.183-193.
- Macfarlane, G., Gibson, G., and Cummings, J., 1992. Comparison of fermentation reactions in different regions of the human colon. *Journal of Applied Bacteriology*, 72, pp.57-64.
- Maltepe, C., and Koren, G., 2013. The management of nausea and vomiting of pregnancy and hyperemesis gravidarum-a 2013 update. *Journal of Population Therapeutics and Clinical Pharmacology*, 20, pp.e184-e194.
- Mamand, D.M., and Qadr, H.M., 2021. Comprehensive spectroscopic and optoelectronic properties of bbl organic semiconductor. *Protection of Metals and Physical Chemistry of Surfaces*, 57, pp.943-953.
- Mamand, D.M., Awla, A.H., Anwer, T.M.K., and Qadr, H.M., 2022a. Quantum chemical study of heterocyclic organic compounds on the corrosion inhibition. *Chimica Techno Acta*, 9, p.20229203.
- Mamand, D.M., Rasul, H.H., Omer, P.K., and Qadr, H.M., 2022b. Theoretical and experimental investigation on ADT organic semiconductor in different solvents. *Condensed Matter and Interphases*, 24, pp.227-242.
- Mary, Y.S., Mary, Y.S., Armaković, S., Armaković, S.J., Yadav, R., Celik, I., Mane, P., and Chakraborty, B., 2021. Stability and reactivity study of biomolecules brucine and colchicine towards electrophile and nucleophile attacks: Insight from DFT and MD simulations. *Journal of Molecular Liquids*, 335, p.116192.
- Omar, R.A., Koparir, P., Sarac, K., Koparir, M., and Safin, D.A., 2023. A novel coumarin-triazole-thiophene hybrid: Synthesis, characterization, ADMET prediction, molecular docking and molecular dynamics studies with a series of SARS-CoV-2 proteins. *Journal of Chemical Sciences (Bangalore)*, 135, p.6.
- Omer, R.A., Koparir, P., and Ahmed, L., 2022. Theoretical determination of corrosion inhibitor activities of 4-allyl-5-(pyridin-4-yl)-4H-1, 2, 4-triazole-3-thiol-thione tautomerism. *Indian Journal of Chemical Technology (IJCT)*, 29, pp.75-81.
- Parlak, A.E., Omar, R.A., Koparir, P., and Salih, M.I., 2022. Experimental, DFT and theoretical corrosion study for 4-(((4-ethyl-5-(thiophen-2-yl)-4H-1, 2, 4-triazole-3-yl) thio) methyl)-7, 8-dimethyl-2H-chromen-2-one. *Arabian Journal of Chemistry*, 15, p.104088.
- Phillips, S., 1984. Functions of the large bowel: an overview. *Scandinavian Journal of Gastroenterology Supplement*, 93, pp.1-12.
- Qadr, H.M., and Mamand, D.M., 2021. Molecular structure and density functional theory investigation corrosion inhibitors of some oxadiazoles. *Journal of Bio-and Tribo-Corrosion*, 7, p.140.
- Samuels, L.A., 2009. Pharmacotherapy update: Hyoscine butylbromide in the treatment of abdominal spasms. *Clinical Medicine Therapeutics*, 1, p.S1134.
- Schulze-Delrieu, K., 1979. Metoclopramide. *Gastroenterology*, 77, pp.768-779.
- Smith, H.S., and Laufer, A., 2014. Opioid induced nausea and vomiting. *European Journal of Pharmacology*, 722, pp.67-78.
- Sumi, M., Kiuchi, K., Ishikawa, T., Ishii, A., Hagiwara, M., Nagatsu, T., and Hidaka, H., 1991. The newly synthesized selective Ca<sup>2+</sup> calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. *Biochemical and Biophysical Research Communications*, 181, pp.968-975.
- Williams, D.M., and Rubin, B.K., 2018. Clinical pharmacology of bronchodilator medications. *Respiratory Care*, 63, pp.641-654.